Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. is a medical diagnostics company dedicated to improving patient outcomes through the development of cost-efficient, rapid, near-patient testing solutions. The company's mission is to provide products for the triage, diagnosis, and monitoring of disease progression. Headquartered in Acton, Massachusetts, Bluejay Diagnostics focuses on addressing critical needs in healthcare by bringing diagnostic capabilities closer to the patient.

Bluejay Diagnostics' primary product is the Symphony System, a near-patient biomarker detection platform. This system comprises an analyzer and single-use cartridges, designed to deliver quantitative clinical chemistry results vital for triage and acute care, particularly for conditions like sepsis. The Symphony platform integrates modern advances in microfluidics, nanotechnology, and enzyme-linked immunosorbent assays (ELISA) to enable rapid, laboratory-quality results in approximately 20-24 minutes. While currently for Research Use Only and not yet FDA cleared for diagnostic use, the company's first product candidate is the Symphony IL-6 Test for sepsis.

Under the leadership of President and CEO Neil Dey, appointed in March 2024, Bluejay Diagnostics is a late-stage, pre-revenue company actively advancing its clinical and commercialization efforts. Recent notable activities include the ongoing SYMON™ II clinical study for its IL-6 test, which has enrolled 624 patients towards a target of 750, and the completion of commercial-scale IL-6 antibody production in December 2025. The company is also progressing manufacturing readiness and regulatory submission planning for the Symphony platform, and executed a 1-for-4 reverse stock split in January 2026.